Skinvisible, Inc. Files 8-K Report
Ticker: SKVI · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1085277
| Field | Detail |
|---|---|
| Company | Skinvisible, Inc. (SKVI) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-statements
Related Tickers: SKVI
TL;DR
SKVI filed an 8-K on Jan 23, 2025, mostly for financial docs.
AI Summary
On January 23, 2025, Skinvisible, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a regulatory disclosure. No specific financial figures or significant business events were detailed in the provided excerpt.
Why It Matters
This 8-K filing serves as a public record of Skinvisible, Inc.'s regulatory disclosures and financial statement submissions to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine regulatory disclosure and does not appear to contain new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Skinvisible, Inc. (company) — Registrant
- January 23, 2025 (date) — Date of Report
- 702-433-7154 (phone_number) — Registrant's telephone number
- NV (state) — State of Incorporation
- 89120 (zip_code) — Business Address Zip Code
FAQ
What is the primary purpose of this 8-K filing for Skinvisible, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was this 8-K report filed by Skinvisible, Inc.?
The 8-K report was filed as of January 23, 2025.
What is Skinvisible, Inc.'s state of incorporation?
Skinvisible, Inc. is incorporated in Nevada (NV).
What is the business address of Skinvisible, Inc.?
The business address of Skinvisible, Inc. is 6320 South Sandhill Road, Unit 9, Las Vegas, NV 89120.
What is the telephone number for Skinvisible, Inc.?
The telephone number for Skinvisible, Inc. is 702-433-7154.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-01-23 15:20:44
Filing Documents
- skvi8k_012325.htm (8-K) — 22KB
- ex99_1.htm (EX-99.1) — 14KB
- 0001663577-25-000033.txt ( ) — 204KB
- skvi-20250123.xsd (EX-101.SCH) — 3KB
- skvi-20250123_lab.xml (EX-101.LAB) — 33KB
- skvi-20250123_pre.xml (EX-101.PRE) — 22KB
- skvi8k_012325_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On January 23, 2025, Skinvisible, Inc. (the "Company") issued a press release concerning achievements in 2024 and 2025, with its license agreement with Quoin Pharmaceuticals and Quoin Pharmaceuticals' progress in treating Netherton Syndrome. A copy of the Company's press release is furnished as Exhibit 99.1 hereto and is incorporated by reference. The information contained in this Item, including the exhibit attached hereto, is being furnished and shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing. SECTION 9 – Financial Statements and Exhibits
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release, dated January 23, 2025 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Skinvisible, Inc. /s/ Terry Howlett Terry Howlett Chief Executive Officer Date: January 23, 2025 3